In an adult with chronic kidney disease and type 2 diabetes mellitus, how should finerenone be initiated, titrated, and monitored regarding dose, estimated glomerular filtration rate (eGFR), serum potassium, and contraindications?

Finerenone Initiation, Titration, and Monitoring in Adults with CKD and Type 2 Diabetes

Start finerenone at 10 mg once daily when eGFR is 25–60 mL/min/1.73 m² or 20 mg once daily when eGFR is ≥60 mL/min/1.73 m², provided serum potassium is ≤4.8 mmol/L, the patient has persistent albuminuria (UACR ≥30 mg/g) despite maximum tolerated ACE inhibitor or ARB, and preferably after adding an SGLT2 inhibitor. 1

Absolute Prerequisites Before Starting Finerenone

• Confirm maximum tolerated RAS inhibitor therapy: The patient must already be on the highest dose of ACE inhibitor or ARB that does not cause unacceptable side effects—finerenone is contraindicated without this foundation therapy. 1, 2
• Verify baseline serum potassium ≤4.8 mmol/L: Do not initiate if potassium exceeds this threshold, as hyperkalemia risk becomes unacceptable. 1, 2
• Document eGFR ≥25 mL/min/1.73 m²: Finerenone has no established dosing or safety data below this threshold and must not be used in end-stage renal disease or dialysis patients. 1, 2
• Confirm persistent albuminuria (UACR ≥30 mg/g): This indicates residual cardiorenal risk despite RAS blockade and defines the eligible population. 1, 3

Treatment Sequencing: Where Finerenone Fits

The KDIGO 2024 hierarchy prioritizes therapies by magnitude of cardiorenal benefit:

1. First-line foundation: Maximum tolerated ACE inhibitor or ARB 1, 2
2. Second-line priority: SGLT2 inhibitor—provides the largest renal and cardiovascular benefit and reduces hyperkalemia risk when combined with finerenone 1, 2
3. Third-line consideration: Finerenone for patients with persistent albuminuria despite SGLT2 inhibitor therapy, or when SGLT2 inhibitors are contraindicated or not tolerated 1, 2, 3

Key clinical point: Do not skip SGLT2 inhibitors to add finerenone first—SGLT2 inhibitors deliver greater absolute risk reduction and actually protect against finerenone-associated hyperkalemia. 1

Initial Dosing Protocol

Baseline eGFR	Starting Dose
25–59 mL/min/1.73 m²	10 mg once daily
≥60 mL/min/1.73 m²	20 mg once daily

1, 2, 3

This eGFR-stratified approach balances efficacy with hyperkalemia risk in patients with reduced kidney function. 1

Dose Titration After 1 Month

Increase from 10 mg to 20 mg daily only if all three conditions are met:

• Serum potassium remains ≤4.8 mmol/L 1, 2
• eGFR is stable (no clinically significant decline) 1, 2
• The medication is well tolerated without adverse effects 1

The 1-month interval captures the predictable early rise in potassium that occurs with mineralocorticoid receptor antagonism. 1

Potassium Monitoring Schedule

• Pre-initiation: Verify potassium ≤4.8 mmol/L 1, 2
• 1 month after start: Check potassium to assess early response 1, 2
• Every 4 months thereafter: Ongoing monitoring during maintenance therapy 1, 2

Potassium-Based Management Algorithm

Serum Potassium (mmol/L)	Action
≤4.8	Continue current dose; monitor every 4 months
4.9–5.5	Continue current dose without adjustment; maintain monitoring every 4 months
>5.5	Hold finerenone immediately; correct dietary potassium, review concomitant medications (NSAIDs, potassium supplements, potassium-sparing diuretics), recheck potassium; restart at 10 mg daily once potassium ≤5.0 mmol/L

1, 2

Critical pitfall to avoid: Do not permanently discontinue finerenone after a single potassium reading >5.5 mmol/L—temporary interruption with dose reduction upon restart (10 mg daily) successfully manages most cases. 1

Additional Monitoring Parameters

• eGFR: Measure at baseline, 1 month, then every 4 months to ensure renal stability 1, 2
• UACR (albuminuria): Obtain at baseline and month 4 to assess treatment response 1

Managing Expected Creatinine Rise

• A serum creatinine increase up to 30% from baseline is an anticipated hemodynamic effect (reduced intraglomerular pressure), not acute kidney injury—continue finerenone if potassium remains ≤5.5 mmol/L and the patient is clinically stable. 2
• Hold finerenone temporarily if creatinine rises >30% from baseline, or if volume depletion, hypotension, acute illness, or nephrotoxin exposure (NSAIDs, contrast, aminoglycosides) is present. 2
• This pattern mirrors ACE inhibitors and ARBs, where modest creatinine elevations reflect beneficial hemodynamic changes and support long-term kidney protection. 2

Absolute Contraindications

• eGFR <25 mL/min/1.73 m² or end-stage renal disease/dialysis 1, 2
• Baseline serum potassium >4.8 mmol/L 1, 2
• Absence of maximum tolerated RAS inhibitor therapy 1, 2

Clinical Benefits (High-Quality Phase 3 Trial Evidence)

Finerenone delivers dual cardiorenal protection in patients with type 2 diabetes and CKD:

• 23% reduction in composite kidney outcome (kidney failure, ≥57% sustained eGFR decline, or renal death) 1, 3
• 36% reduction in progression to end-stage kidney disease 1, 2, 3
• 14% reduction in major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke, or heart failure hospitalization) 1, 3
• 29% reduction in heart failure hospitalization 3

These outcomes derive from the FIDELIO-DKD and FIGARO-DKD randomized controlled trials and the pooled FIDELITY analysis (>13,000 patients, median 3-year follow-up), representing Level A evidence. 1, 3, 4

Safety Profile

• Hyperkalemia (potassium >5.5 mmol/L) occurred in 14% of finerenone patients versus 6.9% with placebo 1, 3
• Permanent discontinuation due to hyperkalemia was rare: 1.7% versus 0.6% with placebo over 3 years 1, 3
• No deaths attributed to hyperkalemia during median 3-year follow-up 1, 3

Protective factor: Concomitant diuretic use reduces hyperkalemia risk in patients receiving finerenone. 1

Risk factor: Lower eGFR, especially <45 mL/min/1.73 m², increases hyperkalemia likelihood. 1

Common Clinical Pitfalls

• Do not use finerenone as monotherapy—it must be added only after maximizing RAS inhibitor therapy (and SGLT2 inhibitor when appropriate). 1, 3
• Do not misinterpret early modest eGFR decline as pathological AKI—a reversible hemodynamic change is expected in the first months and does not require discontinuation if <30% rise and patient is stable. 2
• Do not overlook cardiovascular benefits—finerenone reduces major cardiovascular events, heart failure hospitalization, and sudden cardiac death beyond its antiproteinuric effect. 3
• Do not consider SGLT2 inhibitors and finerenone interchangeable—they have complementary mechanisms and can be combined for additive cardiorenal protection. 3

When to Refer to Nephrology

• eGFR falls below 30 mL/min/1.73 m² (stage 4 CKD) to discuss renal replacement options 2
• Creatinine rise >30% from baseline persists despite holding potential offending agents 2
• Persistent hyperkalemia despite dietary and medication adjustments 2
• Uncertain etiology of kidney disease 2